Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aptevo Therapeutics Inc
(NQ:
APVO
)
0.5810
+0.2460 (+73.43%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aptevo Therapeutics Inc
< Previous
1
2
Next >
Aptevo Therapeutics Announces Closing of $2.75 Million Offering
July 01, 2024
Via
ACCESSWIRE
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules
June 28, 2024
Via
ACCESSWIRE
Aptevo Participating in the BIO International Convention
June 03, 2024
Via
ACCESSWIRE
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
May 14, 2024
Via
ACCESSWIRE
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
May 08, 2024
Via
ACCESSWIRE
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
March 05, 2024
Via
ACCESSWIRE
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
November 14, 2023
Via
ACCESSWIRE
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
August 10, 2023
Via
ACCESSWIRE
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
April 15, 2024
Via
ACCESSWIRE
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
April 11, 2024
Via
ACCESSWIRE
Aptevo Therapeutics Provides Pipeline Update
April 10, 2024
Via
ACCESSWIRE
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
March 18, 2024
Via
ACCESSWIRE
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
March 07, 2024
Via
ACCESSWIRE
Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update
May 11, 2023
Via
ACCESSWIRE
Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update
March 30, 2023
Via
ACCESSWIRE
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding
March 30, 2023
Via
ACCESSWIRE
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
March 04, 2024
Via
ACCESSWIRE
Aptevo to Present at Bio-Europe Conference
November 01, 2023
Via
ACCESSWIRE
Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering
August 04, 2023
Via
ACCESSWIRE
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
August 01, 2023
Via
ACCESSWIRE
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial
February 13, 2023
Via
ACCESSWIRE
Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors
January 09, 2023
Via
ACCESSWIRE
Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 10, 2022
Via
ACCESSWIRE
Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML
July 18, 2023
Via
ACCESSWIRE
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)
December 12, 2022
Via
ACCESSWIRE
Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics
November 09, 2022
Via
ACCESSWIRE
Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
November 03, 2022
Via
ACCESSWIRE
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND
September 19, 2022
Via
ACCESSWIRE
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 11, 2022
Via
ACCESSWIRE
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
June 09, 2022
Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to Date
From
Aptevo Therapeutics
Via
AccessWire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.